Atomo Diagnostics Ltd.ASX: AT1

Quarterly Activity Report & Appendix 4C - 31 December 2020

· Issued by Atomo Diagnostics Ltd.

Filed with ASX · · 13 pages · English

FY21 (unaudited) to $4.5m SYDNEY Australia Wednesday, 27 January 2021 – Australian rapid blood test company quarterly activities report for the three-month period ended 31 December 2020 (Q2 FY21). Atomo’s cash position continues to be strong as customer receipts, and receipt of the Company’s R&D tax rebate supported ongoing investment in inventory, manufacturing COVID‐19rapidtestingdetectsSARS‐COV

Atomo Diagnostics Ltd. on 6ix

Story so far

Earlier from Atomo Diagnostics

Later from Atomo Diagnostics

All Atomo Diagnostics news releases